U.S. Markets open in 7 hrs 9 mins

LifeSci Capital Initiates Coverage of Cellect Biotechnology

Powered by Cellect; Cell Differentiation Technology may Optimize Stem Cell Transplants; Currently Conducting a Phase I/II Trial for Apotainer in Leukemia Patients; Report Available here: http://www.lifescicapital.com/equity-research/cellect/

NEW YORK, NY / ACCESSWIRE / December 7, 2016 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of Cellect Biotechnology (APOP), a biotechnology company based in Israel developing technologies for companies in the regenerative medicine space. The Company's platform technology Powered by CellectTM is designed to functionally select human stem and progenitor cells from a mixed population of cells in order to improve the safety and efficacy of cell therapies. This platform technology, which has broad potential application beyond this particular setting in large diseases such as type 1 diabetes, Crohn's disease, psoriasis, and lupus.

The Company's lead candidate is the Apograft process featuring the Apotainer, a drug/device combination product designed to optimize allogeneic hematopoietic stem cell transplantation (alloHCT) and reduce the risk of graft-versus-host disease (GvHD). Cellect recently initiated a Phase I/II study evaluating the Apograft process in leukemia patients undergoing alloHCT in Israel and plans to enroll the first patient in 2016. Apograft process in the alloHCT setting. The primary objective of this study is to test the safety and tolerability of ApoGraft administered to subjects with hematological malignancies who are undergoing alloHCT. The secondary objective of this trial is to assess ApoGraft engraftment, the donor cells populating patients' hematological systems, and prevention of GvHD.

The Company expects to conduct a pre-IND meeting with the FDA in the first half of 2017 and file an IND in the second half of 2017, which could lead to the commencement of trials in 2018.

In a 24 page Initiation Report, LifeSci Capital describes the Powered by Cellect platform, the Company's plans for developing their lead product candidate to improve stem cell transplants, and future opportunities based on this stem cell differentiation technology in the diabetes and autoimmune disorders.

Dr. Isaacson's full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on Cellect Biotechnology as developments occur.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients' businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company's website, www.lifescicapital.com.

Analyst Contact:

Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com

SOURCE: LifeSci Capital, LLC